# Iopofosine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/iopofosine

> The PDUFA target action date for iopofosine, sponsored by Cellectar Biosciences, Inc. (CLRB), is July 21, 2029. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the iopofosine PDUFA date?

The PDUFA target action date for iopofosine, sponsored by Cellectar Biosciences, Inc. (CLRB), is July 21, 2029. Status: scheduled. SEC Form 10-Q: "The 2024 Tranche A warrants have an exercise price of $75.60 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." Last confirmed November 10, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/iopofosine)

Source: SEC Form 10-Q, accession 0001104659-26-124765, https://www.sec.gov/Archives/edgar/data/1279704/000110465926124765/clrb-20260930x10q.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/pdufa/iopofosine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | iopofosine |
| Codes |  |
| Sponsor | Cellectar Biosciences, Inc. (CLRB) https://sec-api.dev/companies/clrb/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | accelerated, breakthrough, fast track |

## Timeline

### July 21, 2029: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2024-11-18, last confirmed 2026-11-10.
- SEC Form 10-Q (accession 0001104659-26-124765): "The 2024 Tranche A warrants have an exercise price of $75.60 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." https://www.sec.gov/Archives/edgar/data/1279704/000110465926124765/clrb-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095426): "The 2024 Tranche A warrants have an exercise price of $75.60 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." https://www.sec.gov/Archives/edgar/data/1279704/000110465926095426/clrb-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-060678): "The 2024 Tranche A warrants have an exercise price of $75.60 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." https://www.sec.gov/Archives/edgar/data/1279704/000110465926060678/clrb-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-023167): "The 2024 Tranche A warrants have an exercise price of $75.60 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." https://www.sec.gov/Archives/edgar/data/1279704/000110465926023167/clrb-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-110827): "The 2024 Tranche A warrants have an exercise price of $75.60 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." https://www.sec.gov/Archives/edgar/data/1279704/000110465925110827/clrb-20250930x10q.htm
- SEC Form 10-Q (accession 0001410578-25-001778): "The 2024 Tranche A warrants have an exercise price of $75.60 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." https://www.sec.gov/Archives/edgar/data/1279704/000141057825001778/clrb-20250630x10q.htm
- SEC Form 10-Q (accession 0001410578-25-001205): "The 2024 Tranche A warrants have an exercise price of $2.52 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." https://www.sec.gov/Archives/edgar/data/1279704/000141057825001205/clrb-20250331x10q.htm
- SEC Form 10-K (accession 0001410578-25-000329): "The 2024 Tranche A warrants have an exercise price of $2.52 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." https://www.sec.gov/Archives/edgar/data/1279704/000141057825000329/clrb-20241231x10k.htm
- SEC Form 10-Q (accession 0001410578-24-002012): "The 2024 Tranche A warrants have an exercise price of $2.52 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." https://www.sec.gov/Archives/edgar/data/1279704/000141057824002012/clrb-20240930x10q.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/iopofosine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Iopofosine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/iopofosine

```bibtex
@misc{secapidev_pdufa_iopofosine_20261116,
  title        = {Iopofosine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/iopofosine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_iopofosine_20261116","title":"Iopofosine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/iopofosine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
